Meniscus injury adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From February 2005 to June 2026, FDA received 6,079 adverse event reports that record the MedDRA preferred term Meniscus injury. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 299 reports in the 12 months to June 2026 and 306 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 125 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Meniscus injury name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	23
Aclasta		29
Actemra	Interleukin-6 receptor antagonist	46
Actonel	Bisphosphonate	19
Adalimumab	Tumor necrosis factor blocker	14
Alendronate sodium	Bisphosphonate	105
Alphagan P	alpha-Adrenergic agonist	35
Amitriptyline		10
Amlodipine	Calcium channel blocker	19
Ampyra	Potassium channel blocker	35
Anastrozole	Aromatase inhibitor	12
Arava	Antirheumatic agent	57
Aredia		17
Asa		11
Aspirin	Nonsteroidal anti-inflammatory drug	13
Atenolol	beta-Adrenergic blocker	10
Aubagio	Pyrimidine synthesis inhibitor	14
Avonex	Interferon beta	62
Boniva		36
Brilinta	P2Y12 platelet inhibitor	11
Captopril	Angiotensin converting enzyme inhibitor	12
Cefixime	Cephalosporin antibacterial	13
Celebrex	Nonsteroidal anti-inflammatory drug	59
Celecoxib	Nonsteroidal anti-inflammatory drug	11
Certolizumab pegol	Tumor necrosis factor blocker	24
Cimzia	Tumor necrosis factor blocker	11
Cipro	Corticosteroid	20
Ciprofloxacin	Fluoroquinolone antibacterial	49
Codeine		45
Cortisone	Corticosteroid	18
Cosentyx	Interleukin-17A antagonist	109
Creon		14
Crestor	HMG-CoA reductase inhibitor	18
Cyclobenzaprine	Muscle relaxant	19
Desoximetasone	Corticosteroid	40
Diclofenac	Nonsteroidal anti-inflammatory drug	16
Diovan	Angiotensin 2 receptor blocker	17
Doxepin	Tricyclic antidepressant	24
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	16
Dupixent	Interleukin-4 receptor alpha antagonist	79
Eliquis	Factor Xa inhibitor	33
Enbrel	Tumor necrosis factor blocker	415
Entresto	Angiotensin 2 receptor blocker	30
Etanercept	Tumor necrosis factor blocker	12
Flexeril		11
Forteo	Parathyroid hormone analog	34
Fosamax	Bisphosphonate	236
Fosamax Plus D		53
Gilenya	Sphingosine 1-phosphate receptor modulator	28
Humalog	Insulin analog	19
Human immunoglobulin g	Human immunoglobulin G	33
Human Immunoglobulin G Hyaluronidase Recombinant Human		10
Humira		1,568
Hydrochlorothiazide	Thiazide diuretic	17
Hydroxychloroquine	Antimalarial	19
Imbruvica	Kinase inhibitor	40
Inflectra	Tumor necrosis factor blocker	28
Infliximab	Tumor necrosis factor blocker	20
Jakafi	Janus kinase inhibitor	26
Kesimpta	CD20-directed cytolytic antibody	16
Lantus Solostar	Insulin analog	10
Leflunomide	Antirheumatic agent	23
Letrozole	Aromatase inhibitor	11
Levaquin		58
Levofloxacin	Fluoroquinolone antibacterial	25
Lipitor	HMG-CoA reductase inhibitor	12
Lyrica		72
Mavenclad	Purine antimetabolite	10
Metformin	Biguanide	10
Methotrexate	Folate analog metabolic inhibitor	144
Methotrexate sodium	Folate analog metabolic inhibitor	39
Metoprolol	beta-Adrenergic blocker	17
Mirtazapine		24
Moxonidine		12
Multaq	Antiarrhythmic	11
Nexium	Proton pump inhibitor	56
Nortriptyline		10
Novalgin		12
NuvaRing	Estrogen	15
Ocrevus	CD20-directed cytolytic antibody	56
Omeprazole	Proton pump inhibitor	18
Orencia	Selective T cell costimulation modulator	35
Otezla	Phosphodiesterase 4 inhibitor	41
OxyContin	Opioid agonist	11
Ozempic	GLP-1 receptor agonist	28
Prednisolone	Corticosteroid	11
Prednisone	Corticosteroid	40
Prilosec	Proton pump inhibitor	10
Prolia	RANK ligand inhibitor	45
Propecia	5-alpha reductase inhibitor	17
Ranitidine hydrochloride	Histamine-2 receptor antagonist	16
Rebif	Interferon beta	33
Remicade	Tumor necrosis factor blocker	40
Repatha	PCSK9 inhibitor	25
Revlimid	Thalidomide analog	32
Rinvoq	Janus kinase inhibitor	178
Rituxan	CD20-directed cytolytic antibody	24
Rituximab	CD20-directed cytolytic antibody	38
Salazopyrin		26
Seroquel	Atypical antipsychotic	13
Simponi	Tumor necrosis factor blocker	13
Skyrizi	Interleukin-23 antagonist	162
Stelara	Interleukin-12 antagonist	14
Sulfasalazine	Aminosalicylate	60
Synthroid	l-Thyroxine	12
Taltz	Interleukin-17A antagonist	15
Tecfidera		53
Tiotropium bromide	Anticholinergic	13
Tocilizumab	Interleukin-6 receptor antagonist	10
Toradol		36
Tramacet		19
Trulicity	GLP-1 receptor agonist	16
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	12
Tysabri	Integrin receptor antagonist	72
Valsartan	Angiotensin 2 receptor blocker	33
Vedolizumab	Integrin receptor antagonist	25
Verapamil hydrochloride	Calcium channel blocker	11
Voltaren	Nonsteroidal anti-inflammatory drug	11
Vumerity		14
Xalatan	Prostaglandin analog	40
Xarelto	Factor Xa inhibitor	37
Xeljanz	Janus kinase inhibitor	136
Xolair	Anti-IgE	16
Xyrem	Central nervous system depressant	113
Zometa		31

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 44 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Meniscus injury name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	27
alpha-Adrenergic agonist	43
Aminosalicylate	60
Angiotensin 2 receptor blocker	92
Antimalarial	33
Antirheumatic agent	80
Aromatase inhibitor	41
beta-Adrenergic blocker	52
Bisphosphonate	370
Calcium channel blocker	30
CD20-directed cytolytic antibody	144
Central nervous system depressant	120
Corticosteroid	153
Factor Xa inhibitor	77
Fluoroquinolone antibacterial	74
Folate analog metabolic inhibitor	191
GLP-1 receptor agonist	63
HMG-CoA reductase inhibitor	36
Human immunoglobulin G	33
Insulin analog	54
Integrin receptor antagonist	102
Interferon beta	103
Interleukin-17A antagonist	124
Interleukin-23 antagonist	162
Interleukin-4 receptor alpha antagonist	84
Interleukin-6 receptor antagonist	64
Janus kinase inhibitor	340
Kinase inhibitor	67
Muscle relaxant	27
Nonsteroidal anti-inflammatory drug	134
Opioid agonist	53
Parathyroid hormone analog	34
PCSK9 inhibitor	33
Phosphodiesterase 4 inhibitor	41
Potassium channel blocker	40
Prostaglandin analog	48
Proton pump inhibitor	99
RANK ligand inhibitor	45
Selective T cell costimulation modulator	58
Serotonin and norepinephrine reuptake inhibitor	28
Sphingosine 1-phosphate receptor modulator	33
Thalidomide analog	34
Tricyclic antidepressant	30
Tumor necrosis factor blocker	579

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Meniscus injury, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Meniscus injury
Age	Reports	Share
Under 2	2	under 0.1%
2 to 11	2	under 0.1%
12 to 17	25	0.4%
18 to 44	500	8.2%
45 to 64	2,183	35.9%
65 to 74	797	13.1%
75 and over	251	4.1%
Age not given	2,319	38.1%

Sex of the patient in the reports that record Meniscus injury
Sex	Reports	Share
Female	4,148	68.2%
Male	1,654	27.2%
Unknown or not given	277	4.6%

Age and sex are as the report gives them. 75.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Meniscus injury: adverse event reports that record this term. https://reportedreactions.com/reaction/meniscus-injury/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Meniscus injury mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page